A Technology Project of Beijing Handian Pharmaceutical: Honee Taishen Granule for COVID-19

BEIJING, CHINA / ACCESSWIRE / June 22, 2020 / The research team of Handian Pharmaceutical Medical Center and Handian Traditional Chinese Medicine Hospital has devoted to develop a new formula against COVID-19, which in traditional Chinese medicine theory, is differentiated as cold-dampness viral disease with the symptoms of fever, aversion to cold, cough, fatigue, general aching pain, headache, diarrhea, etc. After several months of hardworking, they initially developed Honee Taishen Granule (also known as Handian HD1). Cooperating with Chinese Academy of Medical Sciences and Good Laboratory Practice (GLP) certification agencies, Handian Pharmaceutical Medical Center has completed pharmacy studies. Pharmacology and toxicology tests are still in progress to further evaluate its safety and efficacy.

This formula is derived from a famous traditional Chinese medicine prescription. Its components can eliminate dampness and turbidity, repel foulness and remove toxin, which give it cold-dampness eliminating and antiviral effects. According to traditional Chinese medicine theory, it rectifies taiyin cold damp constitution and restores yin-yang balance of the body, which can help patients regain immunity and prevents the virus from affecting the spleen (pancreas) to damage the body.

Contact:

Xiaoteng Bai
Beijing Handian Science & Technology (Group) Co., Ltd.
Phone: +86 010 5690 3502
Website: http://www.handian.com

SOURCE: :Beijing Handian Science & Technology (Group) Co., Ltd.

View source version on accesswire.com:
https://www.accesswire.com/594856/A-Technology-Project-of-Beijing-Handian-Pharmaceutical-Honee-Taishen-Granule-for-COVID-19

Staff

Recent Posts

Bulletin from the 2024 Annual General Meeting of PMD

STOCKHOLM, SWEDEN / ACCESSWIRE / June 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) The Annual…

35 mins ago

Waystar announces term loan repricing and credit rating upgrades from Fitch, Moody’s, and S&P Global

Reduces Waystar's cost of capital and enhances its ability to allocate free cash flow towards…

13 hours ago

NUTEX HEALTH ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT

HOUSTON, June 27, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…

13 hours ago

Chroma Medicine Announces Exclusive License Agreement with the Whitehead Institute for Novel Epigenetic Editing Technology

License provides exclusive access to innovative epigenetic editors and expands the reach of Chroma's platform…

13 hours ago

Pulmonary Fibrosis Foundation’s 2024 PFF Walk Raises Funds Toward a Cure

Nationwide Walk Series Kicks Off July 20 in Pittsburgh CHICAGO, June 27, 2024 /PRNewswire/ --…

13 hours ago